SA520420102B1 - مركبات حمض أميني وطرق استخدامها - Google Patents
مركبات حمض أميني وطرق استخدامهاInfo
- Publication number
- SA520420102B1 SA520420102B1 SA520420102A SA520420102A SA520420102B1 SA 520420102 B1 SA520420102 B1 SA 520420102B1 SA 520420102 A SA520420102 A SA 520420102A SA 520420102 A SA520420102 A SA 520420102A SA 520420102 B1 SA520420102 B1 SA 520420102B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- formula
- amino acid
- acid compounds
- compounds
- fibrosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
يتعلق الاختراع الحالي بمركبات لها الصيغة (A) والصيغة (I): (A) (I) أو ملح منها، حيث R1، R2، R10، R11، R12، R13، R14، R15، R16، q وp كما هو موصوف هنا. مركبات لها الصيغة (A)، الصيغة (I)، وتكون تركيبات صيدلية منها عبارة عن مثبطات αvβ6 إنتجرين integrin تتسم بأنها مفيدة في علاج التليف fibrosis على سبيل المثال تليف الرئة مجهول السبب idiopathic pulmonary fibrosis (IPF) والتهاب الرئة الخلالي غير النوعي nonspecific interstitial pneumonia (NSIP).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862639988P | 2018-03-07 | 2018-03-07 | |
| US201862690933P | 2018-06-27 | 2018-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA520420102B1 true SA520420102B1 (ar) | 2024-10-20 |
Family
ID=67844341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA520420102A SA520420102B1 (ar) | 2018-03-07 | 2020-09-06 | مركبات حمض أميني وطرق استخدامها |
Country Status (35)
| Country | Link |
|---|---|
| US (4) | US10793564B2 (ar) |
| EP (3) | EP3761980B1 (ar) |
| JP (4) | JP6866535B2 (ar) |
| KR (2) | KR102787602B1 (ar) |
| CN (1) | CN112135612B (ar) |
| AU (1) | AU2019230209B2 (ar) |
| BR (1) | BR112020018064A2 (ar) |
| CA (1) | CA3093225A1 (ar) |
| CL (1) | CL2020002290A1 (ar) |
| CO (1) | CO2020011085A2 (ar) |
| CR (1) | CR20200452A (ar) |
| CU (1) | CU24684B1 (ar) |
| DK (1) | DK3761980T3 (ar) |
| EC (1) | ECSP20063227A (ar) |
| ES (1) | ES2972512T3 (ar) |
| FI (1) | FI3761980T3 (ar) |
| HR (1) | HRP20240234T1 (ar) |
| HU (1) | HUE065887T2 (ar) |
| IL (2) | IL305296A (ar) |
| JO (1) | JOP20200212A1 (ar) |
| LT (1) | LT3761980T (ar) |
| MD (1) | MD3761980T2 (ar) |
| MX (2) | MX2020009253A (ar) |
| PE (2) | PE20251320A1 (ar) |
| PH (1) | PH12020551395A1 (ar) |
| PL (1) | PL3761980T3 (ar) |
| PT (1) | PT3761980T (ar) |
| RS (1) | RS65170B1 (ar) |
| SA (1) | SA520420102B1 (ar) |
| SG (1) | SG11202008609UA (ar) |
| SI (1) | SI3761980T1 (ar) |
| SM (1) | SMT202400155T1 (ar) |
| TW (1) | TW201938158A (ar) |
| WO (1) | WO2019173653A1 (ar) |
| ZA (1) | ZA202005437B (ar) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201823208A (zh) | 2016-09-07 | 2018-07-01 | 美商普萊恩醫療公司 | N－醯基胺基酸化合物及其使用方法 |
| EP3558303A4 (en) | 2016-12-23 | 2020-07-29 | Pliant Therapeutics, Inc. | AMINO ACID COMPOUNDS AND PROCESSES FOR USE |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| CA3054604A1 (en) | 2017-02-28 | 2018-09-07 | Morphic Therapeutic, Inc. | Inhibitors of .alpha.v.beta.6 integrin |
| SI3761980T1 (sl) * | 2018-03-07 | 2024-06-28 | Pliant Therapeutics, Inc. | Aminokislinske spojine in postopki uporabe |
| SG11202012972YA (en) | 2018-06-27 | 2021-01-28 | Bristol Myers Squibb Co | Substituted naphthyridinone compounds useful as t cell activators |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| MX2021002181A (es) | 2018-08-29 | 2021-07-15 | Morphic Therapeutic Inc | Inhibicion de la integrina alfa v beta 6. |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| CN112969504B (zh) | 2018-10-30 | 2024-04-09 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
| CA3114240C (en) | 2018-10-30 | 2023-09-05 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
| EP3873884B1 (en) | 2018-10-30 | 2024-12-04 | Gilead Sciences, Inc. | 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dione derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases |
| CA3115820A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Compounds for inhibition of .alpha.4.beta.7 integrin |
| WO2020210404A1 (en) * | 2019-04-08 | 2020-10-15 | Pliant Therapeutics, Inc. | Dosage forms and regimens for amino acid compounds |
| US11578069B2 (en) | 2019-08-14 | 2023-02-14 | Gilead Sciences, Inc. | Compounds for inhibition of α4 β7 integrin |
| AU2020408067B2 (en) * | 2019-12-20 | 2024-03-28 | Novartis Ag | Combination treatment of liver diseases using integrin inhibitors |
| KR20230049584A (ko) * | 2020-05-07 | 2023-04-13 | 플라이언트 테라퓨틱스, 인크. | 아미노산 화합물을 사용한 호흡기 질환의 치료 |
| KR20230121761A (ko) * | 2020-11-19 | 2023-08-21 | 플라이언트 테라퓨틱스, 인크. | 인테그린 억제제 및 그의 용도 |
| IL308063A (en) * | 2021-04-30 | 2023-12-01 | Pliant Therapeutics Inc | Expanded dosage regimens for integrin inhibitors |
| JP2025518533A (ja) * | 2022-05-18 | 2025-06-17 | プライアント・セラピューティクス・インコーポレイテッド | インテグリン阻害剤の安定化 |
| AU2023406476A1 (en) | 2022-12-02 | 2025-06-05 | Neumora Therapeutics, Inc. | Methods of treating neurological disorders |
| WO2024125634A1 (zh) * | 2022-12-16 | 2024-06-20 | 西藏海思科制药有限公司 | 一种四氢萘啶类化合物及其在医药上的应用 |
| WO2024155965A2 (en) * | 2023-01-21 | 2024-07-25 | Pliant Therapeutics, Inc. | Biomarkers for use in integrin inhibitor therapy |
| WO2024235299A1 (zh) * | 2023-05-17 | 2024-11-21 | 西藏海思科制药有限公司 | 一种羧基衍生物及其在医药上的应用 |
| WO2025024590A1 (en) * | 2023-07-24 | 2025-01-30 | The Johns Hopkins University | Compositions and methods to treat mucus-related diseases |
| WO2025067384A1 (zh) * | 2023-09-28 | 2025-04-03 | 成都微芯药业有限公司 | 一类氨基酸整联蛋白抑制剂、其制备方法及其应用 |
| US20250197393A1 (en) | 2023-12-14 | 2025-06-19 | Pliant Therapeutics, Inc. | Integrin inhibitor and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6361764B2 (en) | 1996-12-13 | 2002-03-26 | Societe L'oreal S.A. | Insoluble s-triazine derivatives and their use as UV filters |
| EA002822B1 (ru) | 1997-12-17 | 2002-10-31 | Мерк Энд Ко., Инк. | Антагонисты рецептора интегрина |
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| PE20020382A1 (es) * | 2000-06-15 | 2002-05-10 | Pharmacia Corp | Derivados de acido heteroarilalcanoico como antagonistas de la integrina |
| JP4272338B2 (ja) | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
| WO2002098849A2 (en) | 2001-06-01 | 2002-12-12 | Elan Pharmaceuticals, Inc. | Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer’s disease and similar diseases |
| DE10233500A1 (de) | 2002-07-24 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel |
| EP1537072A1 (en) | 2002-09-10 | 2005-06-08 | Pharmacia & Upjohn Company LLC | Substituted aminoethers for the treatment of alzheimer s disease |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| EP1870400A1 (en) | 2006-06-08 | 2007-12-26 | Boehringer Ingelheim Pharma GmbH & Co. KG | Salts and crystalline salt forms of an 2-indolinone derivative |
| UA107560C2 (uk) | 2008-06-06 | 2015-01-26 | Фармацевтична лікарська форма для негайного вивільнення похідної індолінону | |
| DK2299987T3 (en) | 2008-06-06 | 2018-05-22 | Boehringer Ingelheim Int | Pharmaceutical Capsule Dosage Form Containing A Suspension Formulation Of An Indolinone Derivative |
| KR20150038185A (ko) * | 2012-07-18 | 2015-04-08 | 세인트 루이스 유니버시티 | 인테그린 길항제로서의 베타 아미노산 유도체 |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| EP3052515A4 (en) | 2013-09-30 | 2017-03-15 | The Regents of the University of California | Anti-alphavbeta1 integrin compounds and methods |
| CA2981371A1 (en) | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| GB201604681D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| RU2759563C2 (ru) | 2016-04-14 | 2021-11-15 | Марс, Инкорпорейтед | Соединения, модулирующие активность кальцийчувствительных рецепторов, для модуляции вкуса кокуми и кормовые продукты для домашних животных, содержащие их |
| CA3029829A1 (en) * | 2016-07-05 | 2018-01-11 | The Rockefeller University | Tetrahydronaphthyridinepentanamide integrin antagonists |
| TW201823208A (zh) | 2016-09-07 | 2018-07-01 | 美商普萊恩醫療公司 | N－醯基胺基酸化合物及其使用方法 |
| CN110062625A (zh) | 2016-12-12 | 2019-07-26 | 勃林格殷格翰国际有限公司 | 尼达尼布通过与奥达特罗共给予用于治疗间质性肺病的方法 |
| EP3558303A4 (en) | 2016-12-23 | 2020-07-29 | Pliant Therapeutics, Inc. | AMINO ACID COMPOUNDS AND PROCESSES FOR USE |
| CA3054604A1 (en) | 2017-02-28 | 2018-09-07 | Morphic Therapeutic, Inc. | Inhibitors of .alpha.v.beta.6 integrin |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| SI3761980T1 (sl) | 2018-03-07 | 2024-06-28 | Pliant Therapeutics, Inc. | Aminokislinske spojine in postopki uporabe |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| ES3027421T3 (en) | 2018-08-29 | 2025-06-13 | Morphic Therapeutic Inc | Inhibitors of (alpha-v)(beta-6) integrin |
| MX2021002181A (es) | 2018-08-29 | 2021-07-15 | Morphic Therapeutic Inc | Inhibicion de la integrina alfa v beta 6. |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| WO2020210404A1 (en) | 2019-04-08 | 2020-10-15 | Pliant Therapeutics, Inc. | Dosage forms and regimens for amino acid compounds |
| KR20230049584A (ko) | 2020-05-07 | 2023-04-13 | 플라이언트 테라퓨틱스, 인크. | 아미노산 화합물을 사용한 호흡기 질환의 치료 |
-
2019
- 2019-03-07 SI SI201930710T patent/SI3761980T1/sl unknown
- 2019-03-07 PL PL19765136.7T patent/PL3761980T3/pl unknown
- 2019-03-07 IL IL305296A patent/IL305296A/en unknown
- 2019-03-07 US US16/296,194 patent/US10793564B2/en active Active
- 2019-03-07 EP EP19765136.7A patent/EP3761980B1/en active Active
- 2019-03-07 EP EP24207882.2A patent/EP4509512A3/en active Pending
- 2019-03-07 KR KR1020207026985A patent/KR102787602B1/ko active Active
- 2019-03-07 IL IL277146A patent/IL277146B2/en unknown
- 2019-03-07 MD MDE20210065T patent/MD3761980T2/ro unknown
- 2019-03-07 FI FIEP19765136.7T patent/FI3761980T3/fi active
- 2019-03-07 RS RS20240183A patent/RS65170B1/sr unknown
- 2019-03-07 MX MX2020009253A patent/MX2020009253A/es unknown
- 2019-03-07 CR CR20200452A patent/CR20200452A/es unknown
- 2019-03-07 PT PT197651367T patent/PT3761980T/pt unknown
- 2019-03-07 SG SG11202008609UA patent/SG11202008609UA/en unknown
- 2019-03-07 JP JP2020521559A patent/JP6866535B2/ja active Active
- 2019-03-07 HU HUE19765136A patent/HUE065887T2/hu unknown
- 2019-03-07 LT LTEPPCT/US2019/021243T patent/LT3761980T/lt unknown
- 2019-03-07 EP EP23205993.1A patent/EP4328230A3/en not_active Withdrawn
- 2019-03-07 PE PE2025000569A patent/PE20251320A1/es unknown
- 2019-03-07 CU CU2020000066A patent/CU24684B1/es unknown
- 2019-03-07 DK DK19765136.7T patent/DK3761980T3/da active
- 2019-03-07 BR BR112020018064-5A patent/BR112020018064A2/pt unknown
- 2019-03-07 PE PE2020001357A patent/PE20201502A1/es unknown
- 2019-03-07 SM SM20240155T patent/SMT202400155T1/it unknown
- 2019-03-07 JO JOP/2020/0212A patent/JOP20200212A1/ar unknown
- 2019-03-07 WO PCT/US2019/021243 patent/WO2019173653A1/en active IP Right Grant
- 2019-03-07 TW TW108107688A patent/TW201938158A/zh unknown
- 2019-03-07 ES ES19765136T patent/ES2972512T3/es active Active
- 2019-03-07 CA CA3093225A patent/CA3093225A1/en active Pending
- 2019-03-07 CN CN201980030750.4A patent/CN112135612B/zh active Active
- 2019-03-07 HR HRP20240234TT patent/HRP20240234T1/hr unknown
- 2019-03-07 AU AU2019230209A patent/AU2019230209B2/en active Active
- 2019-03-07 KR KR1020257009595A patent/KR20250048478A/ko active Pending
-
2020
- 2020-06-26 US US16/914,209 patent/US11560376B2/en active Active
- 2020-08-31 ZA ZA2020/05437A patent/ZA202005437B/en unknown
- 2020-09-04 MX MX2022014456A patent/MX2022014456A/es unknown
- 2020-09-04 CL CL2020002290A patent/CL2020002290A1/es unknown
- 2020-09-06 SA SA520420102A patent/SA520420102B1/ar unknown
- 2020-09-07 CO CONC2020/0011085A patent/CO2020011085A2/es unknown
- 2020-09-07 PH PH12020551395A patent/PH12020551395A1/en unknown
- 2020-10-06 EC ECSENADI202063227A patent/ECSP20063227A/es unknown
-
2021
- 2021-04-07 JP JP2021065309A patent/JP7273882B2/ja active Active
-
2022
- 2022-12-19 US US18/084,307 patent/US20230271960A1/en not_active Abandoned
-
2023
- 2023-04-28 JP JP2023074346A patent/JP7624025B2/ja active Active
-
2024
- 2024-09-13 US US18/885,075 patent/US20250223288A1/en active Pending
-
2025
- 2025-01-17 JP JP2025006716A patent/JP2025081308A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA520420102B1 (ar) | مركبات حمض أميني وطرق استخدامها | |
| CR20210041A (es) | Compuestos de aminoácidos con ligadores no ramificados y métodos de uso | |
| JOP20210056A1 (ar) | مركبات حمض أميني وطرق استخدامها | |
| AR107864A1 (es) | ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS | |
| EA201400553A1 (ru) | Производные 2-(1,2,3-триазол-2-ил)бензамида и 3-(1,2,3-триазол-2-ил)пиколинамида | |
| CL2023003219A1 (es) | Regímenes posológicos ampliados para los inhibidores de integrina. | |
| RS53503B1 (en) | An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase | |
| EA201101301A1 (ru) | Натриевая соль 5-циклопропил-2-{[2-(2,6-дифторфенил)пиримидин-5-ил]амино}бензойной кислоты в качестве ингибиторов dhodh | |
| MX379859B (es) | Compuestos de indolinona y su uso en el tratamiento de enfermedades fibróticas. | |
| CO2020006789A2 (es) | Procedimiento para la preparación de (3s)-3-(4-cloro-3-{[(2s,3r)-2-(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil]amino}fenil)-3-ácido ciclopropilpropanoico y su forma cristalina para uso como principio activo farmacéutico | |
| EA201892020A1 (ru) | Индольные производные и их применение в качестве ингибиторов протеинкиназы | |
| EA202092110A1 (ru) | Аминокислотные соединения и способы применения | |
| MY183976A (en) | Pharmaceutical composition for oral administration with improved dissolution and/or absorption | |
| MX383481B (es) | Procedimiento para la preparación del compuesto n-(3,5-dimetilfenil)-n'-(2-trifluorometilfenil) guanidina. |